By enrolling patients with significant coronary artery disease on DAPT and utilizing a humanized animal model of vascular injury, we demonstrate that FPH has potential value as a therapy to bypass P2Y12 inhibition and restore the hemostatic properties of dysfunctional platelets in vivo. The gene discussed is P2RY12; the disease is coronary artery disorder.